Mostrar el registro sencillo del ítem

dc.contributor.author
Alvarez, Luis Ignacio  
dc.contributor.author
Lanusse, Carlos Edmundo  
dc.contributor.author
Williams, Diana J. L.  
dc.contributor.author
Fairweather, Ian  
dc.contributor.author
Hodgkinson, Jane E.  
dc.contributor.other
Dalton, John Pius  
dc.date.available
2024-02-09T10:24:32Z  
dc.date.issued
2021  
dc.identifier.citation
Alvarez, Luis Ignacio; Lanusse, Carlos Edmundo; Williams, Diana J. L.; Fairweather, Ian; Hodgkinson, Jane E.; Flukicidal drugs: pharmacotherapeutics and drug resistance; CABI; 2021; 211-255  
dc.identifier.isbn
978-1-78924-616-2  
dc.identifier.uri
http://hdl.handle.net/11336/226518  
dc.description.abstract
The purpose of this chapter is to review our current understanding of the action of flukicidesagainst Fasciola hepatica and Fasciola gigantica,particularly the former given the greater body ofwork reported in the literature for this species. Weillustrate how the drugs work and how they areabsorbed, distributed, metabolized and excretedby the host, which in turn dictates exposure of theparasite to the active drug or drug metabolites. Toachieve optimal efficacy, it is vital that a givendrug can gain access and accumulate within theparasite, hence we report on what we know aboutthe main route of drug entry into F. hepatica. Finally, as we face the threat of drug resistance inFasciola spp., we consider how we can determinewhen a parasite population has become resistantto a given drug and how they have evolved andadapted to overcome its effects, especially to thehighly effective drug triclabendazole (TCBZ).  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
CABI  
dc.rights
info:eu-repo/semantics/restrictedAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
FLUKICIDAL  
dc.subject
DRUGS  
dc.subject
PHARMACOTERAPHEUTICS  
dc.subject.classification
Ciencias Veterinarias  
dc.subject.classification
Ciencias Veterinarias  
dc.subject.classification
CIENCIAS AGRÍCOLAS  
dc.title
Flukicidal drugs: pharmacotherapeutics and drug resistance  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.type
info:eu-repo/semantics/bookPart  
dc.type
info:ar-repo/semantics/parte de libro  
dc.date.updated
2024-02-02T15:12:09Z  
dc.journal.pagination
211-255  
dc.journal.pais
Irlanda  
dc.journal.ciudad
Galway  
dc.description.fil
Fil: Alvarez, Luis Ignacio. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina  
dc.description.fil
Fil: Lanusse, Carlos Edmundo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Tandil. Centro de Investigación Veterinaria de Tandil. Universidad Nacional del Centro de la Provincia de Buenos Aires. Centro de Investigación Veterinaria de Tandil. Provincia de Buenos Aires. Gobernación. Comision de Investigaciones Científicas. Centro de Investigación Veterinaria de Tandil; Argentina  
dc.description.fil
Fil: Williams, Diana J. L.. University Of Liverpool. Faculty Of Health And Life Sciences.; Reino Unido  
dc.description.fil
Fil: Fairweather, Ian. The Queens University of Belfast; Irlanda  
dc.description.fil
Fil: Hodgkinson, Jane E.. University Of Liverpool. Faculty Of Health And Life Sciences.; Reino Unido  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.cabidigitallibrary.org/doi/book/10.1079/9781789246162.0000  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.cabidigitallibrary.org/doi/10.1079/9781789246162.0007  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1079/9781789246162.0007  
dc.conicet.paginas
520  
dc.source.titulo
Fasciolosis  
dc.conicet.nroedicion
2